ForPatients
by Roche

Granulomatosis With Polyangiitis

A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

Trial Status	Trial Runs In	Trial Identifier
Completed	8 Countries	NCT01750697 2012-002062-13 WA25615

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase IIa international multicenter, open-label, uncontrolled study will evaluate the safety and pharmacokinetics of rituximab (MabThera/Rituxan) in pediatric participants with severe granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Participants will receive rituximab 375 milligrams per square meter (mg/m^2) intravenously (IV) on Days 1, 8, 15 and 22.

Hoffmann-La Roche	Phase 2
Sponsor	Phase

NCT01750697 2012-002062-13 WA25615
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>=2 Years & <= 17 Years	No